Regulatory News:

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that, at the company's request, the Lyon Economic Activities Court decided on June 11, 2025 to open receivership proceedings against GeNeuro Innovation SAS, the sole subsidiary of GeNeuro SA.

Due to its own financial difficulties, GeNeuro Innovation SAS was obliged to place itself under the protection of the Lyon Commercial Court. The Court appointed SELARL FHBX as receiver.

This decision is part of the restructuring process of the GeNeuro Group, which announced on May 27 that it had obtained a definitive debt-restructuring moratorium in Switzerland for its parent company, GeNeuro SA, a moratorium which is not affected by the receivership of its subsidiary.

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.

For more information, visit: www.geneuro.com

Disclaimer

This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

GeNeuro Jesús Martin-Garcia Chairman and CEO investors@geneuro.com

GeNeuro (EU:GNRO)
Gráfico Histórico do Ativo
De Jun 2025 até Jul 2025 Click aqui para mais gráficos GeNeuro.
GeNeuro (EU:GNRO)
Gráfico Histórico do Ativo
De Jul 2024 até Jul 2025 Click aqui para mais gráficos GeNeuro.